Huawei announced that in cooperation with Huazhong University of Science and Technology, the Chinese Academy of Sciences and other research institutions have screened five antiviral drugs that may be effective for the new 2019 coronavirus (2019-nCoV), and related results will be open to research institutions through Huawei Cloud.
In addition to Huawei Cloud, the research institutions participating in this drug screening are mainly the Basic Medical College of Tongji Medical College of Huazhong University of Science and Technology, Wuhan Children’s Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, the First Affiliated Hospital of Xi’an Jiaotong University, and the Beijing Genomics Institute of Chinese Academy of Sciences, Strong lineup.
The above joint research team targeted ultra-large-scale computer-assisted drug screening of 8,056 drugs that are on the market or are undergoing clinical trials for multiple target proteins of the 2019 new coronavirus (including the Mpro protein crystal structure provided by Rao Zi and the academician team of the Chinese Academy of Sciences). , And achieved the first stage results within a week.
The study found that there are five drugs that may be effective against 2019 new coronaviruses: Beclabuvir, Saquinavir, Bictegravir, Lopinavir, and Dolutegravir.
Related:
